Company Revenue Reports

The company grew in the low double digits in 1Q20 but was on pace for record procedure volumes before COVID-19 impacted the U.S. orthopedic market in mid-March.

While Stryker anticipates significant disruption to orthopedic sales in 2Q20, the company is confident the revenue-generating ability of orthopedics will drive the recovery of deferred procedures.

The company declined 12.5% in 1Q20 and believes the market low point will be in the second quarter. ConMed's orthopedic sales for April are projected to decline by 65%.

DePuy Synthes declined 7.5% in 1Q20 due to the impact of the COVID-19 pandemic, with the worst expected to come in 2Q as procedures are deferred en masse.

Driven by additional favorable reimbursement decisions from payers and an expanding sales force, SI-BONE grew 22% in 2019.

Expansion of its sales force and portfolio drove Orthopediatrics to 26% growth in 2019 as it climbs toward the $100 million annual revenue threshold.

With 12 new product launches and improvement across all major growth metrics, ATEC drove 24% growth in 2019 as it continues to reinvent itself.

Unable to offset the loss of Aetna coverage and the lack of a cementless knee, Conformis sales declined in the low double-digits in 2019.

The company's MACI product drive 35% growth in 2019 and has penetrated just a quarter of Vericel's target addressable market of 5,000 surgeons.